The VizieR database of Astronomical Catalogues

VizieR is a database grouping in an homogeneous way thousands of astronomical catalogues gathered since decades by the Centre de Donnees de Strasbourg (CDS) and participating institutes. The history and current status of this large collection is briefly presented, and the way these catalogues are being standardized to fit in the VizieR system is described. The architecture of the database is then presented, with emphasis on the management of links and of accesses to very large catalogues. Several query interfaces are currently available, making use of the ASU protocol, for browsing purposes or for use by other data processing systems such as visualisation tools.Comment: 10 pages, 2 Postscript figures; to be published in A&A

Southern Durchmusterung (Schoenfeld 1886): Documentation for the machine-readable version

The machine-readable version of the catalog, as it is currently being distributed from the Astronomical Data Center, is described. The Southern Durchmusterung (SD) was computerized at the Centre de Donnees Astronomiques de Strasbourg and at the Astronomical Data Center at the National Space Science Data Center, NASA/Goddard Space Flight Center. Corrigenda listed in the original SD volume and published by Kuenster and Sticker were incorporated into the machine file. In addition, one star indicated to be missing in a published list, and later verified, is flagged so that it can be omitted from computer plotted charts if desired. Stars deleted in the various errata lists were similarly flagged, while those with revised data are flagged and listed in a separate table. This catalog covers the zones -02 to -23 degrees; zones +89 to -01 degrees (the Bonner Durchmusterung) are included in a separate catalog available in machine-readable form

Immunological ignorance of solid tumors

Many peripheral solid tumors such as sarcomas and carcinomas express tumor-specific antigens that can serve as targets for immune effector T cells. Nevertheless, the immune surveillance against clinically manifest carcinomas and sarcomas seems relatively inefficient. Naïve cytotoxic T cells are activated exclusively in secondary lymphoid organs including the spleen and lymph nodes. Tumor antigen might be either cross-presented to naïve cytotoxic T cells by professional antigen-presenting cells (pAPC), or presented directly by tumor cells that migrated to secondary lymphoid organs. Direct priming is quite inefficient during early tumor development because metastasis to lymphoid organs is usually limited to advanced stage diseases. Similarly, the process of cross-priming by pAPC seems to depend on relatively large antigen amounts and on maturation stimuli for dendritic cells, and both requirements may be limiting during initial tumorigenesis. Therefore, the immunosurveillance of solid tumors may fail because they are ignored for too long by the immune system. However, these situations may prove promising for the induction of tumor-specific T cell immunity by vaccination, as the T cell repertoire against these antigens has a naïve phenotype and is not yet affected by tolerance mechanism

Invasive intrauterine Therapie

Zusammenfassung: Einige fetale Fehlbildungen führen bereits intrauterin zu Organschäden, die postpartal schwere bleibende Behinderungen zur Folge haben oder nicht mit dem Leben vereinbar sind. Fetale Eingriffe verlangen eine sichere pränatale Diagnosestellung, Ausschluss assoziierter Fehlbildungen, Reversibilität der schädlichen Krankheitseffekte und deutliche Verbesserung der Prognose durch den fetalen Eingriff an dafür spezialisierten multidisziplinären Therapiezentren. In der invasiven fetalen Therapie wird sowohl offen, wie bei der fetalen Myelomeningozelen(MMC)-Operation, als auch fetoskopisch operiert. Zu nennen sind z.B. die reversible fetoskopische Balloneinlage in die Trachea zur Stimulation des Lungenwachstums bei der kongenitalen Zwerchfellhernie des Feten mit schwerer Lungenhypoplasie oder die Laserkoagulation plazentarer Gefäßverbindungen zum Stopp eines unausgeglichenen Blutflusses beim fetofetalen Transfusionssyndrom (FFTS). Hauptkomplikation der fetalen Chirurgie ist der vorzeitige Blasensprun

Pushing the limits of magnetic anisotropy in trigonal bipyramidal Ni(II)

Monometallic complexes based on 3d transition metal ions in certain axial coordination environments can exhibit appreciably enhanced magnetic anisotropy, important for memory applications, due to stabilisation of an unquenched orbital moment. For high-spin trigonal bipyramidal Ni(II), if competing structural distortions can be minimised, this may result in an axial anisotropy that is at least an order of magnitude stronger than found for orbitally non-degenerate octahedral complexes. Broadband, high-field EPR studies of [Ni(MDABCO)2Cl3]ClO4 (1) confirm an unprecedented axial magnetic anisotropy, which pushes the limits of the familiar spin-only description. Crucially, compared to complexes with multidentate ligands that encapsulate the metal ion, we see only a very small degree of axial symmetry breaking. 1 displays field-induced slow magnetic relaxation, which is rare for monometallic Ni(II) complexes due to efficient spin–lattice and quantum tunnelling relaxation pathways

The ALADIN Interactive Sky Atlas

The Aladin interactive sky atlas, developed at CDS, is a service providing simultaneous access to digitized images of the sky, astronomical catalogues, and databases. The driving motivation is to facilitate direct, visual comparison of observational data at any wavelength with images of the optical sky, and with reference catalogues. The set of available sky images consists of the STScI Digitized Sky Surveys, completed with high resolution images of crowded regions scanned at the MAMA facility in Paris. A Java WWW interface to the system is available at: http://aladin.u-strasbg.fr/Comment: 8 pages, 3 Postscript figures; to be published in A&

Molecular and immunological mechanisms of clonal evolution in multiple myeloma.

Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of clonal plasma cells in the bone marrow (BM). It is known that early genetic mutations in post-germinal center B/plasma cells are the cause of myelomagenesis. The acquisition of additional chromosomal abnormalities and distinct mutations further promote the outgrowth of malignant plasma cell populations that are resistant to conventional treatments, finally resulting in relapsed and therapy-refractory terminal stages of MM. In addition, myeloma cells are supported by autocrine signaling pathways and the tumor microenvironment (TME), which consists of diverse cell types such as stromal cells, immune cells, and components of the extracellular matrix. The TME provides essential signals and stimuli that induce proliferation and/or prevent apoptosis. In particular, the molecular pathways by which MM cells interact with the TME are crucial for the development of MM. To generate successful therapies and prevent MM recurrence, a thorough understanding of the molecular mechanisms that drive MM progression and therapy resistance is essential. In this review, we summarize key mechanisms that promote myelomagenesis and drive the clonal expansion in the course of MM progression such as autocrine signaling cascades, as well as direct and indirect interactions between the TME and malignant plasma cells. In addition, we highlight drug-resistance mechanisms and emerging therapies that are currently tested in clinical trials to overcome therapy-refractory MM stages

Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas

Methylation of the MGMT promoter is supposed to be a predictive and prognostic factor in glioblastoma. Whether MGMT promoter methylation correlates with tumor response to temozolomide in low-grade gliomas is less clear. Therefore, we analyzed MGMT promoter methylation by a quantitative methylation-specific PCR in 22 patients with histologically verified low-grade gliomas (WHO grade II) who were treated with temozolomide (TMZ) for tumor progression. Objective tumor response, toxicity, and LOH of microsatellite markers on chromosomes 1p and 19q were analyzed. Histological classification revealed ten oligodendrogliomas, seven oligoastrocytomas, and five astrocytomas. All patients were treated with TMZ 200mg/m2 on days 1-5 in a 4week cycle. The median progression-free survival was 32months. Combined LOH 1p and 19q was found in 14 patients; one patient had LOH 1p alone and one patient LOH 19q alone. The LOH status could not be determined in two patients and was normal in the remaining four. LOH 1p and/or 19q correlated with longer time to progression but not with radiological response to TMZ. MGMT promoter methylation was detectable in 20 patients by conventional PCR and quantitative analysis revealed the methylation status was between 12 and 100%. The volumetric response to chemotherapy analyzed by MRI and time to progression correlated with the level of MGMT promoter methylation. Therefore, our retrospective case series suggests that quantitative methylation-specific PCR of the MGMT promoter predicts radiological response to chemotherapy with TMZ in WHO grade II glioma